346 related articles for article (PubMed ID: 1612123)
61. Human heparanase is localized within lysosomes in a stable form.
Goldshmidt O; Nadav L; Aingorn H; Irit C; Feinstein N; Ilan N; Zamir E; Geiger B; Vlodavsky I; Katz BZ
Exp Cell Res; 2002 Nov; 281(1):50-62. PubMed ID: 12441129
[TBL] [Abstract][Full Text] [Related]
62. Interaction of lipoprotein lipase with subendothelial extracellular matrix.
Chajek-Shaul T; Friedman G; Bengtsson-Olivecrona G; Vlodavsky I; Bar-Shavit R
Biochim Biophys Acta; 1990 Feb; 1042(2):168-75. PubMed ID: 2302416
[TBL] [Abstract][Full Text] [Related]
63. Neutralization of thrombin by antithrombin III in the presence of cultured human fibroblasts.
Brandt JT; Stephens RE; Hinkle GH
Thromb Res; 1988 Jul; 51(2):187-96. PubMed ID: 2973155
[TBL] [Abstract][Full Text] [Related]
64. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.
Ilan N; Elkin M; Vlodavsky I
Int J Biochem Cell Biol; 2006; 38(12):2018-39. PubMed ID: 16901744
[TBL] [Abstract][Full Text] [Related]
65. The interaction between basic fibroblast growth factor and heparan sulfate can prevent the in vitro degradation of the glycosaminoglycan by Chinese hamster ovary cell heparanases.
Tumova S; Bame KJ
J Biol Chem; 1997 Apr; 272(14):9078-85. PubMed ID: 9083034
[TBL] [Abstract][Full Text] [Related]
66. Mammalian heparanase as mediator of tumor metastasis and angiogenesis.
Vlodavsky I; Elkin M; Pappo O; Aingorn H; Atzmon R; Ishai-Michaeli R; Aviv A; Pecker I; Friedmann Y
Isr Med Assoc J; 2000 Jul; 2 Suppl():37-45. PubMed ID: 10909416
[TBL] [Abstract][Full Text] [Related]
67. Heparanase regulates esophageal keratinocyte differentiation through nuclear translocation and heparan sulfate cleavage.
Kobayashi M; Naomoto Y; Nobuhisa T; Okawa T; Takaoka M; Shirakawa Y; Yamatsuji T; Matsuoka J; Mizushima T; Matsuura H; Nakajima M; Nakagawa H; Rustgi A; Tanaka N
Differentiation; 2006 Jun; 74(5):235-43. PubMed ID: 16759289
[TBL] [Abstract][Full Text] [Related]
68. Inhibition of experimental metastasis and extracellular matrix degradation by butanol extracts from B16-F1 murine melanoma.
Keren Z; Leland F; Nakajima M; LeGrue SJ
Cancer Res; 1989 Jan; 49(2):295-300. PubMed ID: 2910449
[TBL] [Abstract][Full Text] [Related]
69. A solid-phase substrate of heparanase: its application to assay of human melanoma for heparan sulfate degradative activity.
Nakajima M; Irimura T; Nicolson GL
Anal Biochem; 1986 Aug; 157(1):162-71. PubMed ID: 3766958
[TBL] [Abstract][Full Text] [Related]
70. Degradation of basement membrane by prostate tumor heparanase.
Kosir MA; Wang W; Zukowski KL; Tromp G; Barber J
J Surg Res; 1999 Jan; 81(1):42-7. PubMed ID: 9889056
[TBL] [Abstract][Full Text] [Related]
71. Chemically modified heparins as inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells.
Irimura T; Nakajima M; Nicolson GL
Biochemistry; 1986 Sep; 25(18):5322-8. PubMed ID: 3768351
[TBL] [Abstract][Full Text] [Related]
72. The Functions of Heparanase in Human Diseases.
Jin H; Zhou S
Mini Rev Med Chem; 2017; 17(6):541-548. PubMed ID: 27804885
[TBL] [Abstract][Full Text] [Related]
73. Heparanase-1: From Cancer Biology to a Future Antiviral Target.
Lebsir N; Zoulim F; Grigorov B
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680276
[TBL] [Abstract][Full Text] [Related]
74. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior.
Bandari SK; Purushothaman A; Ramani VC; Brinkley GJ; Chandrashekar DS; Varambally S; Mobley JA; Zhang Y; Brown EE; Vlodavsky I; Sanderson RD
Matrix Biol; 2018 Jan; 65():104-118. PubMed ID: 28888912
[TBL] [Abstract][Full Text] [Related]
75. Heparanase is expressed in osteoblastic cells and stimulates bone formation and bone mass.
Kram V; Zcharia E; Yacoby-Zeevi O; Metzger S; Chajek-Shaul T; Gabet Y; Müller R; Vlodavsky I; Bab I
J Cell Physiol; 2006 Jun; 207(3):784-92. PubMed ID: 16514606
[TBL] [Abstract][Full Text] [Related]
76. Heparanase in glomerular diseases.
van den Hoven MJ; Rops AL; Vlodavsky I; Levidiotis V; Berden JH; van der Vlag J
Kidney Int; 2007 Sep; 72(5):543-8. PubMed ID: 17519955
[TBL] [Abstract][Full Text] [Related]
77. A liquid chromatography-mass spectrometry-based approach to characterize the substrate specificity of mammalian heparanase.
Mao Y; Huang Y; Buczek-Thomas JA; Ethen CM; Nugent MA; Wu ZL; Zaia J
J Biol Chem; 2014 Dec; 289(49):34141-51. PubMed ID: 25336655
[TBL] [Abstract][Full Text] [Related]
78. Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis.
Nasser NJ; Avivi A; Shafat I; Edovitsky E; Zcharia E; Ilan N; Vlodavsky I; Nevo E
Proc Natl Acad Sci U S A; 2009 Feb; 106(7):2253-8. PubMed ID: 19164514
[TBL] [Abstract][Full Text] [Related]
79. Mechanisms of heparanase inhibitors in cancer therapy.
Heyman B; Yang Y
Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
[TBL] [Abstract][Full Text] [Related]
80. Structure-activity relationships of heparin-mimicking compounds in induction of bFGF release from extracellular matrix and inhibition of smooth muscle cell proliferation and heparanase activity.
Benezra M; Ishai-Michaeli R; Ben-Sasson SA; Vlodavsky I
J Cell Physiol; 2002 Sep; 192(3):276-85. PubMed ID: 12124773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
